Protocol Ledger

NCT04479917 · Phase II · COMPLETED

Efficacy and Safety of TPN171H in the Patients With Erectile Dysfunction

Interventional Phase II clinical trial protocol NCT04479917 sponsored by Vigonvita Life Sciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-07-23 Enrollment: 255 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04479917
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)255 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04479917
Protocol FieldVerified Registry Value
NCT IdentifierNCT04479917
Consolidated Lead SponsorVigonvita Life Sciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment255 participants (ACTUAL)
Registered Start Date2020-07-23
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI